Diabetes Metab J.  2021 Jan;45(1):27-42. 10.4093/dmj.2020.0216.

Lost in Translation? Measuring Diabetic Neuropathy in Humans and Animals

• Jin HY
• Moon SS
• Calcutt NA

• KMID: 2514071
• DOI: http://doi.org/10.4093/dmj.2020.0216

Abstract

The worldwide diabetes epidemic is estimated to currently afflict almost 500 million persons. Long-term diabetes damages multiple organ systems with the blood vessels, eyes, kidneys and nervous systems being particularly vulnerable. These complications of diabetes reduce lifespan, impede quality of life and impose a huge social and economic burden on both the individual and society. Peripheral neuropathy is a debilitating complication that will impact over half of all persons with diabetes. There is no treatment for diabetic neuropathy and a disturbingly long history of therapeutic approaches showing promise in preclinical studies but failing to translate to the clinic. These failures have prompted re-examination of both the animal models and clinical trial design. This review focuses on the functional and structural parameters used as indices of peripheral neuropathy in preclinical and clinical studies and the extent to which they share a common pathogenesis and presentation. Nerve conduction studies in large myelinated fibers have long been the mainstay of preclinical efficacy screening programs and clinical trials, supplemented by quantitative sensory tests. However, a more refined approach is emerging that incorporates measures of small fiber density in the skin and cornea alongside these traditional assays at both preclinical and clinical phases.

Keyword

Diabetic neuropathies; Electrophysiology; Microscopy, confocal; Models, animal; Neuralgia; Peripheral nervous system

Figure

• 

  Fig. 1 Dermal and epidermal nerves identified using anti-protein gene product 9.5 antibody in human (A, B), rat (C), and mouse (D) skin. Tissue was prepared as either 50 μm frozen sections (A, B) or 6 μm sections cut from paraffin blocks (C, D) with visualization using birghtfield (A, B, D) or immunofluorescence (C) microscopy. (A, B) Image-Pro Plus software (Media Cybernetics Inc.) was used to generate a composite of serial images, alllowing tracking of nerves across multiple planes of section in the dermis and epidermis (A) and around a dermal sweat gland (B). White arrows indicate dermal nerves and yellow arrows indicate epidermal nerves (IENF). Yellow circles surround Langerhans cells and their processes. Images courtesy of Katie Frizzi and Lucie Guernsey.

• 

  Fig. 2 Images of the corneal sub-basal nerve plexus in a human (A) and a BALB/c mouse (B) taken using a corneal confocal microscope (HRT 3 with Rostock Corneal Module; Heidelberg Engineering). The relatively broad and well-defined nerves of the human allow automated image analysis of total nerve length, nerve density and branch points whereas the finer mouse nerves are not accurately detected by current imaging systems and require image enhancement and tracing by hand. Images courtesy of Katie Frizzi and Morgan Cundiff.

• 

  Fig. 3 Therapeutic development funnel designed to identify neuroprotective and regenerative agents for use against diabetic neuropathy. Progression of guaifenesin and M1 receptor (M1R) antagonists through the funnel is indicated by arrows.

• 

Reference

1. International Diabetes Federation. Diabetes Atlas 2019. 9th ed. Brussels: IDF;2019.

2. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabete Metab. 1977; 3:97–107.

3. Velayudhan L, Poppe M, Archer N, Proitsi P, Brown RG, Lovestone S. Risk of developing dementia in people with diabetes and mild cognitive impairment. Br J Psychiatry. 2010; 196:36–40.

4. Pop-Busui R, Martin C. Neuropathy in the DCCT/EDIC: what was done then and what we would do better now. Int Rev Neurobiol. 2016; 127:9–25.

5. Alam U, Sloan G, Tesfaye S. Treating pain in diabetic neuropathy: current and developmental drugs. Drugs. 2020; 80:363–84.

6. Rodriguez-Gutierrez R, Montori VM. Glycemic control for patients with type 2 diabetes mellitus: our evolving faith in the face of evidence. Circ Cardiovasc Qual Outcomes. 2016; 9:504–12.

7. Fernyhough P, Calcutt NA. An introduction to the history and controversies of the pathogenesis of diabetic neuropathy. Int Rev Neurobiol. 2016; 127:115–20.

8. Calcutt NA, Fernyhough P. An introduction to the history and controversies of animal models of diabetic neuropathy. Int Rev Neurobiol. 2016; 127:45–52.

9. Yagihashi S. Glucotoxic mechanisms and related therapeutic approaches. Int Rev Neurobiol. 2016; 127:121–49.

10. Zochodne DW. Sensory neurodegeneration in diabetes: beyond glucotoxicity. Int Rev Neurobiol. 2016; 127:151–80.

11. Bril V. The perfect clinical trial. Int Rev Neurobiol. 2016; 127:27–41.

12. Vinik AI, Casellini C, Nevoret ML. Alternative quantitative tools in the assessment of diabetic peripheral and autonomic neuropathy. Int Rev Neurobiol. 2016; 127:235–85.

13. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017; 40:136–54.

14. Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011; 27:620–8.

15. Zilliox LA, Ruby SK, Singh S, Zhan M, Russell JW. Clinical neuropathy scales in neuropathy associated with impaired glucose tolerance. J Diabetes Complications. 2015; 29:372–7.

16. Kalichman MW, Chalk CH, Mizisin AP. Classification of teased nerve fibers for multicenter clinical trials. J Peripher Nerv Syst. 1999; 4:233–44.

17. Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010; 17:903–12.

18. Petropoulos IN, Ponirakis G, Khan A, Almuhannadi H, Gad H, Malik RA. Diagnosing diabetic neuropathy: something old, something new. Diabetes Metab J. 2018; 42:255–69.

19. Malik RA. Wherefore art thou, o treatment for diabetic neuropathy? Int Rev Neurobiol. 2016; 127:287–317.

20. Kennedy WR, Wendelschafer-Crabb G, Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology. 1996; 47:1042–8.

21. Malik RA, Tesfaye S, Newrick PG, Walker D, Rajbhandari SM, Siddique I, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia. 2005; 48:578–85.

22. Quattrini C, Tavakoli M, Jeziorska M, Kallinikos P, Tesfaye S, Finnigan J, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes. 2007; 56:2148–54.

23. Tavakoli M, Quattrini C, Abbott C, Kallinikos P, Marshall A, Finnigan J, et al. Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care. 2010; 33:1792–7.

24. Tavee J. Nerve conduction studies: basic concepts. Handb Clin Neurol. 2019; 160:217–24.

25. Perkins B, Bril V. Electrophysiologic testing in diabetic neuropathy. Handb Clin Neurol. 2014; 126:235–48.

26. Carrington AL, Shaw JE, Van Schie CH, Abbott CA, Vileikyte L, Boulton AJ. Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period? Diabetes Care. 2002; 25:2010–5.

27. Gibbons CH, Freeman R, Tecilazich F, Dinh T, Lyons TE, Gnardellis C, et al. The evolving natural history of neurophysiologic function in patients with well-controlled diabetes. J Peripher Nerv Syst. 2013; 18:153–61.

28. Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia. 2008; 51:562–6.

29. Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet. 1998; Dec. 352:1978–81.

30. Polydefkis M, Arezzo J, Nash M, Bril V, Shaibani A, Gordon RJ, et al. Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy. J Peripher Nerv Syst. 2015; 20:363–71.

31. Javed S, Petropoulos IN, Tavakoli M, Malik RA. Clinical and diagnostic features of small fiber damage in diabetic polyneuropathy. Handb Clin Neurol. 2014; 126:275–90.

32. Lee-Kubli C, Marshall AG, Malik RA, Calcutt NA. The H-reflex as a biomarker for spinal disinhibition in painful diabetic neuropathy. Curr Diab Rep. 2018; 18:1.

33. Ishikawa K, Ott K, Porter RW, Stuart D. Low frequency depression of the H wave in normal and spinal man. Exp Neurol. 1966; 15:140–56.

34. Kakinohana O, Hefferan MP, Nakamura S, Kakinohana M, Galik J, Tomori Z, et al. Development of GABA-sensitive spasticity and rigidity in rats after transient spinal cord ischemia: a qualitative and quantitative electrophysiological and histopathological study. Neuroscience. 2006; 141:1569–83.

35. Jolivalt CG, Lee CA, Ramos KM, Calcutt NA. Allodynia and hyperalgesia in diabetic rats are mediated by GABA and depletion of spinal potassium-chloride co-transporters. Pain. 2008; 140:48–57.

36. Lee-Kubli CA, Calcutt NA. Altered rate-dependent depression of the spinal H-reflex as an indicator of spinal disinhibition in models of neuropathic pain. Pain. 2014; 155:250–60.

37. Marshall AG, Lee-Kubli C, Azmi S, Zhang M, Ferdousi M, Mixcoatl-Zecuatl T, et al. Spinal disinhibition in experimental and clinical painful diabetic neuropathy. Diabetes. 2017; 66:1380–90.

38. Serra J. Microneurography: towards a biomarker of spontaneous pain. Pain. 2012; 153:1989–90.

39. Kleggetveit IP, Namer B, Schmidt R, Helas T, Ruckel M, Orstavik K, et al. High spontaneous activity of C-nociceptors in painful polyneuropathy. Pain. 2012; 153:2040–7.

40. Ochoa JL, Campero M, Serra J, Bostock H. Hyperexcitable polymodal and insensitive nociceptors in painful human neuropathy. Muscle Nerve. 2005; 32:459–72.

41. Serra J. Microneurography: an opportunity for translational drug development in neuropathic pain. Neurosci Lett. 2010; 470:155–7.

42. Serra J, Duan WR, Locke C, Sola R, Liu W, Nothaft W. Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Pain. 2015; 156:2175–83.

43. Dyck PJ, Dyck PJ, Larson TS, O’Brien PC, Velosa JA. Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve growth factor study group. Diabetes Care. 2000; 23:510–7.

44. Backonja MM, Attal N, Baron R, Bouhassira D, Drangholt M, Dyck PJ, et al. Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. Pain. 2013; 154:1807–19.

45. Bird SJ, Brown MJ, Spino C, Watling S, Foyt HL. Value of repeated measures of nerve conduction and quantitative sensory testing in a diabetic neuropathy trial. Muscle Nerve. 2006; 34:214–24.

46. Gelber DA, Pfeifer MA, Broadstone VL, Munster EW, Peterson M, Arezzo JC, et al. Components of variance for vibratory and thermal threshold testing in normal and diabetic subjects. J Diabetes Complications. 1995; 9:170–6.

47. Shy ME, Frohman EM, So YT, Arezzo JC, Cornblath DR, Giuliani MJ, et al. Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003; 60:898–904.

48. Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008; 131(Pt 7):1912–25.

49. Wahren J, Foyt H, Daniels M, Arezzo JC. Long-acting C-peptide and neuropathy in type 1 diabetes: a 12-month clinical trial. Diabetes Care. 2016; 39:596–602.

50. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987; 30:191–7.

51. Zelman DC, Gore M, Dukes E, Tai KS, Brandenburg N. Validation of a modified version of the Brief Pain Inventory for painful diabetic peripheral neuropathy. J Vasc Nurs. 2005; 23:97–104.

52. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004; 108:248–57.

53. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994; 17:1281–9.

54. Abraham A, Barnett C, Katzberg HD, Lovblom LE, Perkins BA, Bril V. Toronto Clinical Neuropathy Score is valid for a wide spectrum of polyneuropathies. Eur J Neurol. 2018; 25:484–90.

55. Powell HC, Rosoff J, Myers RR. Microangiopathy in human diabetic neuropathy. Acta Neuropathol. 1985; 68:295–305.

56. Kalichman MW, Powell HC, Mizisin AP. Reactive, degenerative, and proliferative Schwann cell responses in experimental galactose and human diabetic neuropathy. Acta Neuropathol. 1998; 95:47–56.

57. Llewelyn JG, Gilbey SG, Thomas PK, King RH, Muddle JR, Watkins PJ. Sural nerve morphometry in diabetic autonomic and painful sensory neuropathy. A clinicopathological study. Brain. 1991; 114(Pt 2):867–92.

58. Mizisin AP, Nelson RW, Sturges BK, Vernau KM, Lecouteur RA, Williams DC, et al. Comparable myelinated nerve pathology in feline and human diabetes mellitus. Acta Neuropathol. 2007; 113:431–42.

59. Sima AA, Bril V, Nathaniel V, McEwen TA, Brown MB, Lattimer SA, et al. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med. 1988; 319:548–55.

60. Sima AA, Greene DA, Brown MB, Hohman TC, Hicks D, Graepel GJ, et al. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group. J Diabetes Complications. 1993; 7:157–69.

61. Breiner A, Lovblom LE, Perkins BA, Bril V. Does the prevailing hypothesis that small-fiber dysfunction precedes large-fiber dysfunction apply to type 1 diabetic patients? Diabetes Care. 2014; 37:1418–24.

62. Lauria G, Bakkers M, Schmitz C, Lombardi R, Penza P, Devigili G, et al. Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst. 2010; 15:202–7.

63. Pittenger GL, Mehrabyan A, Simmons K, Amandarice , Dublin C, Barlow P, et al. Small fiber neuropathy is associated with the metabolic syndrome. Metab Syndr Relat Disord. 2005; 3:113–21.

64. Azmi S, Jeziorska M, Ferdousi M, Petropoulos IN, Ponirakis G, Marshall A, et al. Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantation. Diabetologia. 2019; 62:1478–87.

65. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst. 2010; 15:79–92.

66. Doss AL, Smith PG. Nerve-Langerhans cell interactions in diabetes and aging. Histol Histopathol. 2012; 27:1589–98.

67. Collongues N, Samama B, Schmidt-Mutter C, Chamard-Witkowski L, Debouverie M, Chanson JB, et al. Quantitative and qualitative normative dataset for intraepidermal nerve fibers using skin biopsy. PLoS One. 2018; 13:e0191614.

68. Cheng HT, Dauch JR, Porzio MT, Yanik BM, Hsieh W, Smith AG, et al. Increased axonal regeneration and swellings in intraepidermal nerve fibers characterize painful phenotypes of diabetic neuropathy. J Pain. 2013; 14:941–7.

69. Cheung A, Podgorny P, Martinez JA, Chan C, Toth C. Epidermal axonal swellings in painful and painless diabetic peripheral neuropathy. Muscle Nerve. 2015; 51:505–13.

70. Lauria G, Morbin M, Lombardi R, Borgna M, Mazzoleni G, Sghirlanzoni A, et al. Axonal swellings predict the degeneration of epidermal nerve fibers in painful neuropathies. Neurology. 2003; 61:631–6.

71. Khoshnoodi M, Truelove S, Polydefkis M. Effect of diabetes type on long-term outcome of epidermal axon regeneration. Ann Clin Transl Neurol. 2019; 6:2088–96.

72. Wang N, Gibbons CH. Skin biopsies in the assessment of the autonomic nervous system. Handb Clin Neurol. 2013; 117:371–8.

73. Smith AG, Ramachandran P, Tripp S, Singleton JR. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy. Neurology. 2001; 57:1701–4.

74. Kluding PM, Pasnoor M, Singh R, Jernigan S, Farmer K, Rucker J, et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications. 2012; 26:424–9.

75. Singleton JR, Marcus RL, Jackson JE, Lessard MK, Graham TE, Smith AG. Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Transl Neurol. 2014; 1:844–9.

76. Smith AG, Russell J, Feldman EL, Goldstein J, Peltier A, Smith S, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006; 29:1294–9.

77. Perkins BA, Lovblom LE, Bril V, Scarr D, Ostrovski I, Orszag A, et al. Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. Diabetologia. 2018; 61:1856–61.

78. Dabbah MA, Graham J, Petropoulos IN, Tavakoli M, Malik RA. Automatic analysis of diabetic peripheral neuropathy using multi-scale quantitative morphology of nerve fibres in corneal confocal microscopy imaging. Med Image Anal. 2011; 15:738–47.

79. Williams BM, Borroni D, Liu R, Zhao Y, Zhang J, Lim J, et al. An artificial intelligence-based deep learning algorithm for the diagnosis of diabetic neuropathy using corneal confocal microscopy: a development and validation study. Diabetologia. 2020; 63:419–30.

80. Malik RA, Kallinikos P, Abbott CA, van Schie CH, Morgan P, Efron N, et al. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia. 2003; 46:683–8.

81. Petropoulos IN, Alam U, Fadavi H, Marshall A, Asghar O, Dabbah MA, et al. Rapid automated diagnosis of diabetic peripheral neuropathy with in vivo corneal confocal microscopy. Invest Ophthalmol Vis Sci. 2014; 55:2071–8.

82. Petropoulos IN, Manzoor T, Morgan P, Fadavi H, Asghar O, Alam U, et al. Repeatability of in vivo corneal confocal microscopy to quantify corneal nerve morphology. Cornea. 2013; 32:e83–9.

83. Chen X, Graham J, Dabbah MA, Petropoulos IN, Ponirakis G, Asghar O, et al. Small nerve fiber quantification in the diagnosis of diabetic sensorimotor polyneuropathy: comparing corneal confocal microscopy with intraepidermal nerve fiber density. Diabetes Care. 2015; 38:1138–44.

84. Dehghani C, Pritchard N, Edwards K, Russell AW, Malik RA, Efron N. Risk factors associated with corneal nerve alteration in type 1 diabetes in the absence of neuropathy: a longitudinal in vivo corneal confocal microscopy study. Cornea. 2016; 35:847–52.

85. Jia X, Wang X, Wang X, Pan Q, Xian T, Yu X, et al. In vivo corneal confocal microscopy detects improvement of corneal nerve parameters following glycemic control in patients with type 2 diabetes. J Diabetes Res. 2018; 2018:8516276.

86. Jolivalt CG, Frizzi KE, Guernsey L, Marquez A, Ochoa J, Rodriguez M, et al. Peripheral neuropathy in mouse models of diabetes. Curr Protoc Mouse Biol. 2016; 6:223–55.

87. Gardiner NJ, Freeman OJ. Can diabetic neuropathy be modeled in vitro? Int Rev Neurobiol. 2016; 127:53–87.

88. Goncalves NP, Vaegter CB, Andersen H, Ostergaard L, Calcutt NA, Jensen TS. Schwann cell interactions with axons and microvessels in diabetic neuropathy. Nat Rev Neurol. 2017; 13:135–47.

89. Hadimani MB, Purohit MK, Vanampally C, Van der Ploeg R, Arballo V, Morrow D, et al. Guaifenesin derivatives promote neurite outgrowth and protect diabetic mice from neuropathy. J Med Chem. 2013; 56:5071–8.

90. Habash T, Saleh A, Roy Chowdhury SK, Smith DR, Fernyhough P. The proinflammatory cytokine, interleukin-17A, augments mitochondrial function and neurite outgrowth of cultured adult sensory neurons derived from normal and diabetic rats. Exp Neurol. 2015; 273:177–89.

91. Takaku S, Yako H, Niimi N, Akamine T, Kawanami D, Utsunomiya K, et al. Establishment of a myelinating co-culture system with a motor neuron-like cell line NSC-34 and an adult rat Schwann cell line IFRS1. Histochem Cell Biol. 2018; 149:537–43.

92. Urban MJ, Li C, Yu C, Lu Y, Krise JM, McIntosh MP, et al. Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice. ASN Neuro. 2010; 2:e00040.

93. Biessels GJ, Bril V, Calcutt NA, Cameron NE, Cotter MA, Dobrowsky R, et al. Phenotyping animal models of diabetic neuropathy: a consensus statement of the diabetic neuropathy study group of the EASD (Neurodiab). J Peripher Nerv Syst. 2014; 19:77–87.

94. Beiswenger KK, Calcutt NA, Mizisin AP. Epidermal nerve fiber quantification in the assessment of diabetic neuropathy. Acta Histochem. 2008; 110:351–62.

95. Chen DK, Frizzi KE, Guernsey LS, Ladt K, Mizisin AP, Calcutt NA. Repeated monitoring of corneal nerves by confocal microscopy as an index of peripheral neuropathy in type-1 diabetic rodents and the effects of topical insulin. J Peripher Nerv Syst. 2013; 18:306–15.

96. Jakobsen J. Axonal dwindling in early experimental diabetes. II. A study of isolated nerve fibres. Diabetologia. 1976; 12:547–53.

97. Jakobsen J. Axonal dwindling in early experimental diabetes. I. A study of cross sectioned nerves. Diabetologia. 1976; 12:539–46.

98. Jakobsen J, Sidenius P, Gundersen HJ, Osterby R. Quantitative changes of cerebral neocortical structure in insulin-treated long-term streptozocin-induced diabetes in rats. Diabetes. 1987; 36:597–601.

99. Sidenius P, Jakobsen J. Reduced perikaryal volume of lower motor and primary sensory neurons in early experimental diabetes. Diabetes. 1980; 29:182–6.

100. Thomas PK, Fraher JP, O’Leary D, Moran MA, Cole M, King RH. Relative growth and maturation of axon size and myelin thickness in the tibial nerve of the rat. 2. Effect of streptozotocin-induced diabetes. Acta Neuropathol. 1990; 79:375–86.

101. Anderson NJ, King MR, Delbruck L, Jolivalt CG. Role of insulin signaling impairment, adiponectin and dyslipidemia in peripheral and central neuropathy in mice. Dis Model Mech. 2014; 7:625–33.

102. Sima AA. Encephalopathies: the emerging diabetic complications. Acta Diabetol. 2010; 47:279–93.

103. Biessels GJ, Nobili F, Teunissen CE, Simo R, Scheltens P. Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. Lancet Neurol. 2020; 19:699–710.

104. Kennedy JM, Zochodne DW. Experimental diabetic neuropathy with spontaneous recovery: is there irreparable damage? Diabetes. 2005; 54:830–7.

105. Mattingly GE, Fischer VW. Peripheral neuropathy following prolonged exposure to streptozotocin-induced diabetes in rats: a teased nerve fiber study. Acta Neuropathol. 1983; 59:133–8.

106. Powell HC, Myers RR. Axonopathy and microangiopathy in chronic alloxan diabetes. Acta Neuropathol. 1984; 65:128–37.

107. Robertson DM, Sima AA. Diabetic neuropathy in the mutant mouse [C57BL/ks(db/db)]: a morphometric study. Diabetes. 1980; 29:60–7.

108. Wada R, Koyama M, Mizukami H, Odaka H, Ikeda H, Yagihashi S. Effects of long-term treatment with alpha-glucosidase inhibitor on the peripheral nerve function and structure in Goto-Kakizaki rats: a genetic model for type 2 diabetes. Diabetes Metab Res Rev. 1999; 15:332–7.

109. Yagihashi S, Nishihira M, Baba M. Morphometrical analysis of the peripheral nerve lesions in experimental diabetes rats. Tohoku J Exp Med. 1979; 129:139–49.

110. Gregory JA, Jolivalt CG, Goor J, Mizisin AP, Calcutt NA. Hypertension-induced peripheral neuropathy and the combined effects of hypertension and diabetes on nerve structure and function in rats. Acta Neuropathol. 2012; 124:561–73.

111. Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes. 1997; 46:665–70.

112. Romanovsky D, Hastings SL, Stimers JR, Dobretsov M. Relevance of hyperglycemia to early mechanical hyperalgesia in streptozotocin-induced diabetes. J Peripher Nerv Syst. 2004; 9:62–9.

113. Romanovsky D, Cruz NF, Dienel GA, Dobretsov M. Mechanical hyperalgesia correlates with insulin deficiency in normoglycemic streptozotocin-treated rats. Neurobiol Dis. 2006; 24:384–94.

114. Romanovsky D, Dobretsov M. Pressure-induced pain: early sign of diabetes-associated impairment of insulin production in rats. Neurosci Lett. 2010; 483:110–3.

115. Pabbidi RM, Cao DS, Parihar A, Pauza ME, Premkumar LS. Direct role of streptozotocin in inducing thermal hyperalgesia by enhanced expression of transient receptor potential vanilloid 1 in sensory neurons. Mol Pharmacol. 2008; 73:995–1004.

116. Andersson DA, Filipovic MR, Gentry C, Eberhardt M, Vastani N, Leffler A, et al. Streptozotocin stimulates the ion channel TRPA1 directly: involvement of peroxynitrite. J Biol Chem. 2015; 290:15185–96.

117. Karunanayake EH, Hearse DJ, Mellows G. The synthesis of [14C] streptozotocin and its distribution and excretion in the rat. Biochem J. 1974; 142:673–83.

118. Davidson E, Coppey L, Lu B, Arballo V, Calcutt NA, Gerard C, et al. The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy. Exp Diabetes Res. 2009; 2009:431980.

119. Yorek MA. Alternatives to the streptozotocin-diabetic rodent. Int Rev Neurobiol. 2016; 127:89–112.

120. Walker D, Carrington A, Cannan SA, Sawicki D, Sredy J, Boulton AJ, et al. Structural abnormalities do not explain the early functional abnormalities in the peripheral nerves of the streptozotocin diabetic rat. J Anat. 1999; 195(Pt 3):419–27.

121. Tomlinson DR, Moriarty RJ, Mayer JH. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor sorbinil. Diabetes. 1984; 33:470–6.

122. Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets. 2008; 9:14–36.

123. Coderre TJ, Laferriere A. The emergence of animal models of chronic pain and logistical and methodological issues concerning their use. J Neural Transm (Vienna). 2020; 127:393–406.

124. Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev. 2001; 53:597–652.

125. Lee-Kubli CA, Calcutt NA. Painful neuropathy: mechanisms. Handb Clin Neurol. 2014; 126:533–57.

126. Calcutt NA, Malmberg AB, Yamamoto T, Yaksh TL. Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats. Pain. 1994; 58:413–20.

127. Ohsawa M, Kashiwazaki T, Kamei J. Modulation of the formalin-induced nociceptive response by diabetes: possible involvement of protein kinase C. Brain Res. 1998; 803:198–203.

128. Calcutt NA. Modeling diabetic sensory neuropathy in rats. Methods Mol Med. 2004; 99:55–65.

129. Themistocleous AC, Ramirez JD, Shillo PR, Lees JG, Selvarajah D, Orengo C, et al. The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy. Pain. 2016; 157:1132–45.

130. Jourdan D, Ardid D, Eschalier A. Analysis of ultrasonic vocalisation does not allow chronic pain to be evaluated in rats. Pain. 2002; 95:165–73.

131. Chen X, Levine JD. Hyper-responsivity in a subset of C-fiber nociceptors in a model of painful diabetic neuropathy in the rat. Neuroscience. 2001; 102:185–92.

132. Khan GM, Chen SR, Pan HL. Role of primary afferent nerves in allodynia caused by diabetic neuropathy in rats. Neuroscience. 2002; 114:291–9.

133. Schuelert N, Gorodetskaya N, Just S, Doods H, Corradini L. Electrophysiological characterization of spinal neurons in different models of diabetes type 1- and type 2-induced neuropathy in rats. Neuroscience. 2015; 291:146–54.

134. Chen SR, Pan HL. Hypersensitivity of spinothalamic tract neurons associated with diabetic neuropathic pain in rats. J Neurophysiol. 2002; 87:2726–33.

135. Tan AM, Samad OA, Fischer TZ, Zhao P, Persson AK, Waxman SG. Maladaptive dendritic spine remodeling contributes to diabetic neuropathic pain. J Neurosci. 2012; 32:6795–807.

136. Pertovaara A, Wei H, Kalmari J, Ruotsalainen M. Pain behavior and response properties of spinal dorsal horn neurons following experimental diabetic neuropathy in the rat: modulation by nitecapone, a COMT inhibitor with antioxidant properties. Exp Neurol. 2001; 167:425–34.

137. Calcutt NA, Stiller C, Gustafsson H, Malmberg AB. Elevated substance-P-like immunoreactivity levels in spinal dialysates during the formalin test in normal and diabetic rats. Brain Res. 2000; 856:20–7.

138. Malmberg AB, O’Connor WT, Glennon JC, Cesena R, Calcutt NA. Impaired formalin-evoked changes of spinal amino acid levels in diabetic rats. Brain Res. 2006; 1115:48–53.

139. Wei H, Viisanen H, Amorim D, Koivisto A, Pertovaara A. Dissociated modulation of conditioned place-preference and mechanical hypersensitivity by a TRPA1 channel antagonist in peripheral neuropathy. Pharmacol Biochem Behav. 2013; 104:90–6.

140. Wagner K, Lee KS, Yang J, Hammock BD. Epoxy fatty acids mediate analgesia in murine diabetic neuropathy. Eur J Pain. 2017; 21:456–65.

141. Wagner K, Yang J, Inceoglu B, Hammock BD. Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy. J Pain. 2014; 15:907–14.

142. Agarwal N, Helmstadter J, Rojas DR, Bali KK, Gangadharan V, Kuner R. Evoked hypoalgesia is accompanied by tonic pain and immune cell infiltration in the dorsal root ganglia at late stages of diabetic neuropathy in mice. Mol Pain. 2018; 14:17448–06918817975.

143. Davidson EP, Coppey LJ, Holmes A, Yorek MA. Changes in corneal innervation and sensitivity and acetylcholine-mediated vascular relaxation of the posterior ciliary artery in a type 2 diabetic rat. Invest Ophthalmol Vis Sci. 2012; 53:1182–7.

144. Beiswenger KK, Calcutt NA, Mizisin AP. Dissociation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice. Neurosci Lett. 2008; 442:267–72.

145. Calcutt NA, Chen P, Hua XY. Effects of diabetes on tissue content and evoked release of calcitonin gene-related peptide-like immunoreactivity from rat sensory nerves. Neurosci Lett. 1998; 254:129–32.

146. Tomlinson DR, Fernyhough P, Diemel LT. Neurotrophins and peripheral neuropathy. Philos Trans R Soc Lond B Biol Sci. 1996; 351:455–62.

147. Fernyhough P, Calcutt NA. New directions in diabetic neuropathy: evolution or extinction? Int Rev Neurobiol. 2016; 127:229–34.

148. Davidson EP, Coppey LJ, Shevalye H, Obrosov A, Kardon RH, Yorek MA. Impaired corneal sensation and nerve loss in a type 2 rat model of chronic diabetes is reversible with combination therapy of menhaden oil, α-lipoic acid, and enalapril. Cornea. 2017; 36:725–31.

149. Calcutt NA, Smith DR, Frizzi K, Sabbir MG, Chowdhury SK, Mixcoatl-Zecuatl T, et al. Selective antagonism of muscarinic receptors is neuroprotective in peripheral neuropathy. J Clin Invest. 2017; 127:608–22.